GPLB Green Planet Bio Engineering Co. Ltd.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1392449 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-28.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets—
Debt / equity—
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.32x
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| SG&A expense | $35,842 | $35,544 | $47,370 | $32,533 | $32,929 |
| Interest expense | $0 | $0 | $300 | $0 | — |
| Pretax income | -$35,842 | -$35,544 | -$47,670 | -$32,533 | -$32,929 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$35,842 | -$35,544 | -$47,670 | -$32,533 | -$32,929 |
| EPS (basic) | — | — | — | — | 0.00 |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Weighted avg. shares (diluted) | 20.01M | 20.01M | 20.01M | — | 20.01M |
| Balance sheet | |||||
| Cash & equivalents | $0 | $0 | $0 | $0 | $0 |
| Current assets | $0 | $0 | $0 | $0 | $0 |
| Total assets | — | — | — | — | — |
| Current liabilities | $500,976 | $465,134 | $429,590 | $381,920 | $349,387 |
| Total liabilities | $500,976 | $465,134 | $429,590 | $381,920 | $349,387 |
| Shareholders' equity | -$500,976 | -$465,134 | -$429,590 | -$381,920 | -$349,387 |
| Shares outstanding | 20.01M | 20.01M | 20.01M | 20.01M | 20.01M |
| Cash flow statement | |||||
| Operating cash flow | -$36,544 | -$35,044 | -$42,670 | -$32,533 | -$32,929 |
| Investing cash flow | — | $35,044 | $42,670 | $0 | — |
| Financing cash flow | $36,544 | $35,044 | $42,670 | $32,533 | $32,929 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.